**Result**

 **Table (1):** Demographic and clinical data of TDT children and control

|  |  |  |  |
| --- | --- | --- | --- |
| **p-value** | **Control**N = 60 | **TDT children**N = 60 | **Variables** |
| 0.6 | 13.3±4 | 13 ± 4.1 | **Age (years):** Mean ±SD |
| 0.3 | 32(53.3%) | 38(63.3%) | **Sex:** Male: n (%) |
|  **1.000** | 32(53.3%) | 32(53.3%) | **Consanguinity:** Positive: n (%) |
|  **0.04\*** | 19.3±15.4 | 17.4± 2.8 | **BMI**: Mean ±SD |
| **<0.001**\* | 0(0%) | 38(63.3%) | **Liver:** Hepatomegaly: n (%) |
| **<0.001**\* | 0(0%) | 18(30%) | **Spleen:** Splenomegaly: n (%) |

BMI: body mass index

\* Statistical significance< 0.05

**Table (2):** Additional clinical data of the studied TDT children

Hb: hemoglobin

|  |  |
| --- | --- |
| **Variable** | **N= 60** |
| **Age of start blood transfusion (months):** Mean ±SD | 19.2 ±19 |
| **Pre transfusion Hb (gm%)**: Mean ±SD | 6 ±0.7 |
| **Splenectomy:** Yes: n (%) | 34(57%) |
| **Age of start chelation therapy** **(years)**: Mean ±SD | 7±4.2 |
| **Manifestations of decompensated liver disease:** **n (%)** | 0(0%) |

\* Statistical significance< 0.05

 **Table (3):** laboratory data of TDT children and control

|  |  |
| --- | --- |
| **Variable** | **N= 60** |
| Hb (gm%): Mean ±SDALT (iu/l): Mean ±SDAST (iu/l): Mean ±SDFerritin (ng/ml): Mean ±SDHCV Abs**:** Positive: n (%) | 9.4±0.977.5±54.266.3±42.044282.5±261212(20%) |

ALT: alanine-amino transferase; AST: aspartase-transferase; HCV Abs: hepatitis C virus antibodies.

\* Statistical significance< 0.05